News
November 12, 2021

Regenstrief and IU Fairbanks researcher honored with statewide healthcare award

Regenstrief research scientist Nir Menachemi, PhD, MPH, received the Indiana Healthcare Executives Network (iHEN) service excellence award for his work responding to the COVID-19 pandemic. Dr. Menachemi is also the Fairbanks Endowed Chair, professor and health policy and management department chair at the Indiana University Richard M. Fairbanks School of Public Health. 

The iHEN service excellence award honors an individual who has demonstrated dedication in providing exceptional service to citizens and healthcare workers in Indiana. Recognized for his work on the Indiana prevalence study and other pandemic response activities, Dr. Menachemi and his team partnered with state and local officials and hospital executives to support real-time decisions made about the pandemic. In addition, the award acknowledged his leadership in training health administration and public health students in Indiana.

“This award recognizes the hard work and sacrifices of our faculty and staff in response to the pandemic,” said Dr. Menachemi. “I am fortunate to work with a great set of colleagues both inside the Fairbanks School and within partner organizations around the state. From COVID-19 research and practice, to assuring the success of our students, each member of our faculty and staff has made an indelible mark on Indiana’s health in the last 18 months.”

  • Dr. Menachemi

Related News

Rachel Patzer, PhD

Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa

Published in JAMA Dermatology. Here is a link to the article.   Regenstrief Institute authors:  Rachel Patzer, PhD, MPH

Thomas Imperiale

Next generation stool DNA test has best detection rate of noninvasive colorectal cancer screening tools

Study of highly sensitive noninvasive test published in New England Journal of Medicine A study of more than 21,000

Rachel Patzer, PhD, MPH and Kalli Koukounas, MPH

JAMA study finds facilities treating poor patients penalized by CMS payment model

Social risk and treatment for end-stage kidney disease A new study of more than 2,000 dialysis facilities randomized to